A Pilot Study: Decreased Hospitalization in Elderly Heart Failure Patients While on Sacubitril-Valsartan Combination

Sacubitril-Valsartan combination (SVC) is new to the heart failure (HF) armamentarium. SVC, in addition to HF goal directed medical therapy (GDMT), is indicated to reduce the risk of cardiovascular (CV) death and HF hospitalizations in patients with reduced ejection fraction (HFrEF). PARADIGM-HF was stopped early due to overwhelming efficacy when compared to Enalapril. SVC dosed to the target 97/103 mg twice daily, reduced the primary composite outcomes of CV death or first HF hospitalization by 20%.
Source: Journal of Cardiac Failure - Category: Cardiology Authors: Tags: 433 Source Type: research